PARPi after PARPi in epithelial ovarian cancer

The objective of this study was to describe the treatment experience of patients with recurrent epithelial ovarian cancer who are retreated with an inhibitor of poly(ADP-ribose)-polymerase (PARPi). We conducted a multi-institutional, retrospective review of ovarian cancer patients who received ≥2 li...

Descripción completa

Detalles Bibliográficos
Autores principales: Essel, K.G., Behbakht, K., Lai, T., Hand, L., Evans, E., Dvorak, J., Ding, K., Konecny, G., Moore, K.N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7840844/
https://www.ncbi.nlm.nih.gov/pubmed/33537389
http://dx.doi.org/10.1016/j.gore.2021.100699

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7840844/
https://www.ncbi.nlm.nih.gov/pubmed/33537389
http://dx.doi.org/10.1016/j.gore.2021.100699

Ejemplares similares